A WIDE ARRAY OF IN VIVO MODELS TO ASSESS COMPLEX METABOLIC DISORDERS.
Obesity & Diabetes
We offer a complete suite of animal models for the evaluation of novel therapeutics. Although none of the models can completely capture the complexity of human metabolic syndrome, each model mimics certain aspects of the disease.
A non-human primate model is by far the most predictive animal model system for human metabolic syndrome, presenting complex symptoms such as loss of blood glucose control, diabetic nephropathy, diabetic retinopathy, and dyslipidemia. This is especially critical since many next generation drugs for metabolic disease target diabetic complications rather than blood glucose control. Evaluating drugs in such models will offer tremendous value towards understanding efficacy, PK/PD relationship, biomarker, and possible adverse effects. CrownBio has the largest group in the world of well-documented Cynomolgus and Rhesus monkeys with naturally occurring diabetes. Compared with NHP models, Minipig and rodent models have the advantage of lower cost and higher throughput, especially for evaluating compounds which may still be in early discovery phase.
Our experienced scientific team will work closely with our clients to design the most relevant study plan, and provide high quality service to advance their discovery programs.
Non-human primate models of metabolic disease
Non-Human Primate (NHP) models can be used to study:
- Spontaneous diabetes.
- Diabetic nephropathy.
- Diet-induced dyslipidemia.
Non-Human Primate (NHP) models with spontaneously developed diabetes mirror every aspects of the human disease, including:
- Glucose intolerance.
- Reduced glucose disposition.
- Insulin resistance (Euglycemic &hyperinsulinemic clamp).
- Insulin dependency at late stage.
- High-fat-induced dyslipidemia.
Our in vivo pharmacology expertise in diabetic NHPs provide the highest level of confidence for the go/no go decision making in the drug discovery process. Such studies can not only provide deep biological insights into the pharmacological mechanisms of a drug, but also help to identify biomarkers important to clinical trial design (i.e. patient stratification and study rationale).
Type 2 diabetes is a major risk factor in the development of atherosclerosis in humans. However, studies examining mechanisms underlying diabetes-accelerated atherosclerosis are often limited by the lack of suitable humanoid animal models. Pigs have a cardiovascular system that is very similar to that of humans and are therefore useful as a model for human physiology and pathophysiology.
We have validated a diet-induced minipig model to support the development of novel therapeutics.
Rodent models play an important role in our understanding of the disease and provide important information in drug development due to their ease of handling, high reproducibility, and low cost. Crown Bioscience offers a complete suite of models for in vivo compound testing. Our experienced scientific team can also develop new models specific to your needs.
Some of the rodent models available for new drug development are:
- FATZO mouse
- Ob/ob mouse
- Db/db mouse
- STZ induced mouse
- STZ induced rat
- GK (Goto-Kakizaki) rat
- Diet induced obesity mouse
- ZDSD rat
Contact us today to discuss your project needs and experience the value of our expert service.